Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

Blog | Dave Fornell, DAIC Editor | March 26, 2015

Insights to Key Trials and Technology at ACC 2015

The biggest technology news coming out of the 2015 American College of Cardiology (ACC) annual scientific sessions involved the overwhelmingly positive late-breaking trial data for transcatheter aortic and mitral valve repair. ACC dedicated an entire day of late-breaking trial presentations to this new technology, highlighting its importance in how cardiology will be changing in the coming years, moving from invasive surgical repairs to minimally invasive percutaneous therapies. There were reservations a couple years ago among most cardiologists that transcatheter procedures would not live up to the durability and outcome standards set by surgical valve replacement, but data continue to show it is comparable, and in some cases, better. 

Watch a video explaining trends in the ACC.15 TAVR data

The poster child for transcatheter aortic valve replacement (TAVR) last year at ACC.14 was the Medtronic CoreValve, which showed a trend toward better outcomes than surgical repair. It maintained that trend in 2015, with this year’s two-year results showing CoreValve patients faired better than surgical valve replacement patients. This result stirred conjecture in a couple sessions I attended that the question in the future may change from who is best served by TAVR, to who is best served by surgery? Read about the CoreValve two-year results. 

The Edwards Lifesciences Sapien valve also performed well. The final five-year PARTNER Trial data for high-risk patients treated with the first-generation Sapien valve demonstrated equivalent outcomes to traditional open-heart surgery. There was also no structural valve deterioration requiring intervention. Additionally, data for the improved Sapien 3 device demonstrated lower death, stroke and paravalvular leak rates than earlier generation devices in high and intermediate risk patients in the PARTNER II S3 Trial. The Sapien 3 uses a skirt of material at its base to better seal the annulus to prevent paravalvular leak. 

The clinical data for a TAVR embolic protection system was also presented for the Keystone Heart TriGuard system being tested in the DEFLECT III trial. It showed a 10 percent reduction in stroke rates. 

Interventional Cardiology

The SYNTAX trials several years ago attempted to show drug-eluting stents (DES) could provide outcomes as durable as coronary artery bypass graft (CABG) surgery, but it ended with surgery edging out stents. The BEST trial presented at ACC.15 was a rematch using current generation DES, which was expected to perform better than the Taxus stent used in SYNTAX. However, results were disappointing, with surgical outcomes again trumping DES. Data show patients receiving angioplasty with newer everolimus-eluting stents had a 47 percent higher risk of one of the outcomes identified as a primary endpoint in the study — death, heart attack and subsequent procedure to clear blocked arteries — as compared to patients who received CABG.

Cardiac CT Imaging  

Two trials highlighted at ACC show a continuation of supporting data to use computed tomography angiography (CTA) as the primary diagnostic exam for patients who present with chest pain. The SCOT-HEART Trial (The Scottish Computed Tomography of the Heart Trial), which included more than 4,000 patients, showed a 38 percent reduction in the number of heart attacks in patients who received a CT scan compared with the control group getting the standard of care. The study also showed CTA changed patients’ diagnosis in about 25 percent of cases, whereas using the standard of care diagnosis were only changed about 1 percent of the time. 

The PROMISE Trial showed CTA is extraordinarily effective in accurately diagnosing patients with low to moderate chest pain. In most cases, coronary CTA is at least as effective as diagnostic methods, such as stress tests including SPECT myocardial perfusion imaging, data show. 

New Technology

There were several new cardiovascular technologies showcased on the ACC expo floor. Watch the video Editor’s Choice of the Most Innovative New Technology to see some of my choices for the most interesting new devices. 

 

 

Related Content

rivaroxaban, asprin, venous thromboembolism, VTE recurrence, clinical study, ACC.17
News | Antiplatelet and Anticoagulation Therapies| March 23, 2017
March 23, 2017 — In patients at elevated risk for a recurrence of potentially life- threatening blood clots, a low do
microbleeds, brain bleeds caused by TAVR

An MRI brain scan showing multiple microbleeds in a transcatheter aortic valve replacement (TAVR) patient from the study.

Feature | Heart Valve Technology| March 23, 2017
March 22, 2017 — A quarter of the patients in a single-center study of 84 patients undergoing transcatheter aortic va
PCSK9 inhibitors, bococizumab, ACC .17, clinical trials, LDL cholesterol
News | Pharmaceuticals| March 22, 2017
In a clinical program that was terminated early, the experimental PCSK9 inhibitor bococizumab, when given on top of...
closed loop stimulation, DDD-CLS, ACC17, SPAIN trial
Feature | Pacemakers| March 22, 2017
March 22, 2017 — Patients with recurrent fainting episodes (syncope) who received a pacemaker delivering a pacing pro
Cardiogard embolic protection system for surgical valve reaplacement

The CardioGard embolic protection system for surgical aortic valve replacement.

Feature | Embolic Protection Devices| March 22, 2017
March 22, 2017 — Two U.S.
ACC.17 late breaking trial presentations, ACC late-breakers,  American College of Cardiology late breaking studies
Feature | ACC| March 22, 2017
Here is a list of the American College of Cardiology (ACC) 2017 annual meeting late-breaking clinical trials presente
RESOLVE study, RESOLVE trial, subclinical leaflet thrombosis

A CT study from the RESOLVE Trial showing valve leaflet thrombosis on a TAVR device. The trial examined a range of surgical and transcatheter valves to show thrombosis is found across both types of devices. It also examined if anticoagulation or antiplatelet therapy could reduce thrombosis and allow a greater range of leaflet motion.

Feature | Heart Valve Technology| March 21, 2017
March 21, 2017 — About 12 percent of patients undergoing aortic valve replacement developed non-symptomatic blood clo
highly sensitive troponin testing
News | Cardiac Diagnostics| March 21, 2017
March 21, 2017 — A blood test for a protein called high-sensitivity troponin T, which is released into the bloodstrea
Overlay Init